Personalis (PSNL) has received a United Kingdom Conformity Assessed marking for its NeXT Personal Dx test, the company said Tuesday.
The regulatory milestone allows for clinical use of Personalis' residual disease detection technology in England, Wales, and Scotland, the company said.
The marking confirms that the test meets the UK's safety, health, and performance standards, the company said.